Complementary strategies to elucidate T helper cell epitopes in myasthenia gravis

Journal of Neuroimmunology

Volumn 201-202, Issue C, 2008, Pages 41-49

  Jung, Christine ^a   Stoeckle, Christina ^b   Wiesmüller, Karl Heinz ^c   Laub, Rüdiger ^d   Emmrich, Frank ^d   Jung, Günther ^a,c   Melms, Arthur ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c EMC MICROCOLLECTIONS GMBH   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Acetylcholine receptor; Myasthenia gravis; T cell epitopes

Indexed keywords

CHOLINERGIC RECEPTOR; HLA DR3 ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; HELPER CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 51649098143     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.06.010     Document Type: Article

References (42)

1. Ahlberg R., Yi Q., Pirskanen R., Matell G., Swerup C., Rieber E.P., Riethmuller G., Holm G., and Lefvert A.K. Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T-cell autoreactivity. Neurology 44 (1994) 1732-1737
2. Bradley D.S., Nabozny G.H., Cheng S., Zhou P., Griffiths M.M., Luthra H.S., and David C.S. HLA-DQB1 polymorphism determines incidence, onset, and severity of collagen-induced arthritis in transgenic mice. Implications in human rheumatoid arthritis. J. Clin. Invest. 100 (1997) 2227-2234
3. Bruno R., Sabater L., Tolosa E., Sospedra M., Ferrer-Francesch X., Coll J., Foz M., Melms A., and Pujol-Borrell R. Different patterns of nicotinic acetylcholine receptor subunit transcription in human thymus. J. Neuroimmunol. 149 (2004) 147-159
4. Conti-Fine B.M., Milani M., and Kaminski H.J. Myasthenia gravis: past, present, and future. J. Clin. Invest. 116 (2006) 2843-2854
5. Das P., Drescher K.M., Geluk A., Bradley D.S., Rodriguez M., and David C.S. Complementation between specific HLA-DR and HLA-DQ genes in transgenic mice determines susceptibility to experimental autoimmune encephalomyelitis. Hum. Immunol. 61 (2000) 279-289
6. Fleckenstein, Burkhard, and Wiesmuller K.-H. Quantitative analysis of peptide-MHC class II interaction. Semin. Immunol. 11 (1999) 405-416
7. Gaertner S., de Graaf K.L., Wienhold W., Wiesmuller K.H., Melms A., and Weissert R. Lack of pathogenicity of immunodominant T and B cell determinants of the nicotinic acetylcholine receptor epsilon-chain. J. Neuroimmunol. 152 (2004) 44-56
8. Hawke S., Matsuo H., Nicolle M., Malcherek G., Melms A., and Willcox N. Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Immunol. Today 17 (1996) 307-311
9. Hill M., Beeson D., Moss P., Jacobson L., Bond A., Corlett L., Newsom-Davis J., Vincent A., and Willcox N. Early-onset myasthenia gravis: a recurring T-cell epitope in the adult-specific acetylcholine receptor epsilon subunit presented by the susceptibility allele HLA-DR52a. Ann. Neurol. 45 (1999) 224-231
10. Hohlfeld R., and Wekerle H. The role of the thymus in myasthenia gravis. Adv. Neuroimmunol. 4 (1994) 373-386
11. Hohlfeld R., Toyka K.V., Heininger K., Grosse-Wilde H., and Kalies I. Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature 310 (1984) 244-246
12. Jung C., Kalbus M., Fleckenstein B., Melms A., Jung G., and Wiesmuller K.H. New ligands for HLA DRB1*0301 by random selection of favourable amino acids ranked by competition studies with undecapeptide amide sublibraries. J. Immunol. Methods 219 (1998) 139-149
13. Kaul R., Shenoy M., Goluszko E., and Christadoss P. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 152 (1994) 3152-3157
14. Laub R., Dorsch M., Meyer D., Ermann J., Hedrich H.J., and Emmrich F. A multiple transgenic mouse model with a partially humanized activation pathway for helper T cell responses. J. Immunol. Methods 246 (2000) 37-50
15. MacLennan C.A., Beeson D., Willcox N., Vincent A., and Newsom-Davis J. Muscle nicotinic acetylcholine receptor mRNA expression in hyperplastic and neoplastic myasthenia gravis thymus. Ann. N. Y. Acad. Sci. 841 (1998) 407-410
16. Madsen L.S., Andersson E.C., Jansson L., krogsgaard M., Andersen C.B., Engberg J., Strominger J.L., Svejgaard A., Hjorth J.P., Holmdahl R., Wucherpfennig K.W., and Fugger L. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. 23 (1999) 343-347
17. Malcherek G., Falk K., Rotzschke O., Rammensee H.G., Stevanovic S., Gnau V., Jung G., and Melms A. Natural peptide ligand motifs of two HLA molecules associated with myasthenia gravis. Int. Immunol. 5 (1993) 1229-1237
18. Malcherek G., Gnau V., Stevanovic S., Rammensee H.G., Jung G., and Melms A. Analysis of allele-specific contact sites of natural HLA-DR17 ligands. J. Immunol. 153 (1994) 1141-1149
19. Malcherek G., Wirblich C., Willcox N., Rammensee H.G., Trowsdale J., and Melms A. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation. Eur. J. Immunol. 28 (1998) 1524-1533
20. Matsuo H., Batocchi A.P., Hawke S., Nicolle M., Jacobson L., Vincent A., Newsom-Davis J., and Willcox N. Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor. J. Immunol. 155 (1995) 3683-3692
21. Melms A., Schalke B.C., Kirchner T., Muller-Hermelink H.K., Albert E., and Wekerle H. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J. Clin. Invest. 81 (1988) 902-908
22. Melms A., Malcherek G., Gern U., Wietholter H., Muller C.A., Schoepfer R., and Lindstrom J. T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: heterogeneity of antigenic sites on the alpha-subunit. Ann. Neurol. 31 (1992) 311-318
23. Moudgil K.D., and Sercarz E.E. Understanding crypticity is the key to revealing the pathogenesis of autoimmunity. Trends Immunol. 26 (2005) 355-359
24. Nagvekar N., Corlett L., Jacobson L.W., Matsuo H., Chalkley R., Driscoll P.C., Deshpande S., Spack E.G., and Willcox N. Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor. J. Immunol. 162 (1999) 4079-4087
25. Navaneetham D., Penn A.S., Howard Jr. J.F., and Conti-Fine B.M. Human thymuses express incomplete sets of muscle acetylcholine receptor subunit transcripts that seldom include the delta subunit. Muscle Nerve 24 (2001) 203-210
26. Price P., Witt C., Allcock R., Sayer D., Garlepp M., Kok C.C., French M., Mallal S., and Christiansen F. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol. Rev. 167 (1999) 257-274
27. Protti M.P., Manfredi A.A., Horton R.M., Bellone M., and Conti-Tronconi B.M. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol. Today 14 (1993) 363-368
28. Salvetti M., Jung S., Chang S.F., Will H., Schalke B.C., and Wekerle H. Acetylcholine receptor-specific T-lymphocyte clones in the normal human immune repertoire: target epitopes, HLA restriction, and membrane phenotypes. Ann. Neurol. 29 (1991) 508-516
29. Sommer N., Harcourt G.C., Willcox N., Beeson D., and Mewsom-Davis J. Acetylcholine receptor-reactive T lymphocytes from healthy subjects and myasthenia gravis patients. Neurology 41 (1991) 1270-1276
30. Sonderstrup G., and McDevitt H. Identification of autoantigen epitopes in MHC class II transgenic mice. Immunol. Rev. 164 (1998) 129-138
31. Tolosa E., Li W., Yasuda Y., Wienhold W., Denzin L.K., Lautwein A., Driessen C., Schnorrer P., Weber E., Stevanovic S., Kurek R., Melms A., and Bromme D. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J. Clin. Invest. 112 (2003) 517-526
32. Tompkins S.M., Rota P.A., Moore J.C., and Jensen P.E. A europium fluoroimmunoassay for measuring binding of antigen to class II MHC glycoproteins. J. Immunol. Methods 163 (1993) 209-216
33. Viken M.K., Sollid H.D., Joner G., Dahl-Jorgensen K., Ronningen K.S., Undlien D.E., Flato B., Selvaag A.M., Forre O., Kvien T.K., Thorsby E., Melms A., Tolosa E., and Lie B.A. Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis. Hum. Immunol. 68 (2007) 748-755
34. Villadangos J.A., Schnorrer P., and Wilson N.S. Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. Immunol. Rev. 207 (2005) 191-205
35. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat. Rev., Immunol. 2 (2002) 797-804
36. Vincent A., Newsom-Davis J., Newton P., and Beck N. Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology 33 (1983) 1276-1282
37. Vincent A., Willcox N., Hill M., Curnow J., MacLennan C., and Beeson D. Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunol. Rev. 164 (1998) 157-168
38. Wakkach A., Guyon T., Bruand C., Tzartos S., Cohen-Kaminsky S., and Berrih-Aknin S. Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J. Immunol. 157 (1996) 3752-3760
39. Watts C., Moss C.X., Mazzeo D., West M.A., Matthews S.P., Li D.N., and Manoury B. Creation versus destruction of T cell epitopes in the class II MHC pathway. Ann. N. Y. Acad. Sci. 987 (2003) 9-14
40. Wekerle H., Hohlfeld R., Ketelsen U.P., Kalden J.R., and Kalies I. Thymic myogenesis, T-lymphocytes and the pathogenesis of myasthenia gravis. Ann. N. Y. Acad. Sci. 377 (1981) 455-476
41. Yang H., Goluszko E., David C., Okita D.K., Conti-Fine B., Chan T.S., Poussin M.A., and Christadoss P. Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. J. Clin. Invest. 109 (2002) 1111-1120
42. Yang H., Kala M., Scott B.G., Goluszko E., Chapman H.A., and Christadoss P. Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis. J. Immunol. 174 (2005) 1729-1737